Cardiac glycosides display selective efficacy for STK11 mutant lung cancer

Cardiac glycosides display selective efficacy for STK11 mutant lung cancer

Although STK11 (LKB1) mutation is a major mediator of lung cancer progression, targeted therapy has not been implemented due to STK11 mutations being loss-of-function. Here, we report that targeting the Na+/K+-ATPase (ATP1A1) is synthetic lethal with STK11 mutations in lung cancer. The cardiac glyco...

Full description

Bibliographic Details
Main Authors: Kim, Nayoung, Yim, Hwa Young, He, Ningning, Lee, Cheol-Jung, Kim, Ju Hyun, Choi, Jin-Sung, Lee, Hye Suk, Kim, Somin, Jeong, Euna, Song, Mee, Jeon, Sang-Min, Kim, Woo-Young, Mills, Gordon B., Cho, Yong-Yeon, Yoon, Sukjoon
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949473/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949473/

Similar Items